Mostrar el registro sencillo del ítem
dc.contributor.author
Kornblihtt, Laura Inés
dc.contributor.author
Carreras, Maria Cecilia
dc.contributor.author
Blanco, Guillermo Armando C.
dc.contributor.other
Schneider, Marion
dc.date.available
2022-07-12T11:47:45Z
dc.date.issued
2016
dc.identifier.citation
Kornblihtt, Laura Inés; Carreras, Maria Cecilia; Blanco, Guillermo Armando C.; Targeting mitophagy in combined therapies of haematological malignancies; IntechOpen; 2016; 411-431
dc.identifier.isbn
978-953-51-4815-9
dc.identifier.uri
http://hdl.handle.net/11336/161825
dc.description.abstract
Mitophagy is a selective form of autophagy that eliminates mitochondria, and ispart of a larger network of mitochondrial quality control processes that respond tomitochondrial damage. Treatment of haematological malignancies often involves drugs thatultimately cause cell death by mitochondrial injury and initiation of apoptosis. Thus,mitophagy is a potential cause of resistance to anticancer drugs that target the mitochondria(mitocans). Since mitophagy is integrated to mitochondrial biogenesis, mitochondrial fissionand fusion, the bioenergetics profile and metabolic reprogramming of tumour cells, theblockage of mitophagy may not be sufficient to overcome resistance. In addition, themitochondrial unfolded protein response and the outer mitochondrial membrane associateddegradation have extensive crosstalk with mitophagy, and advanced forms of neoplasmswill require targeting both systems. Proteasome inhibitors and vinca alkaloids target manyof the critical steps involved in resistance to mitocans, while inducers of mitochondrialturnover (biogenesis and mitophagy) like valproic acid have a variable effect depending onmetabolic reprograming and the activity of oxidative phosphorylation of tumour cells. Herewe discuss the mechanisms of mitophagy and its associated mechanisms, and discuss itsapplication to the rationale of targeted combined therapies of low and high-grade B-cellneoplasms.
dc.format
application/pdf
dc.language.iso
eng
dc.publisher
IntechOpen
dc.rights
info:eu-repo/semantics/restrictedAccess
dc.rights.uri
https://creativecommons.org/licenses/by-nc-sa/2.5/ar/
dc.subject
Mitocans
dc.subject
Arsenic Trioxide
dc.subject
BNIP3
dc.subject
Parkin
dc.subject
Aggresome
dc.subject
Proteasome Inhibitors
dc.subject
Chronic Lymphocytic Leukemia (CLL)
dc.subject.classification
Biología Celular, Microbiología
dc.subject.classification
Ciencias Biológicas
dc.subject.classification
CIENCIAS NATURALES Y EXACTAS
dc.title
Targeting mitophagy in combined therapies of haematological malignancies
dc.type
info:eu-repo/semantics/publishedVersion
dc.type
info:eu-repo/semantics/bookPart
dc.type
info:ar-repo/semantics/parte de libro
dc.date.updated
2022-07-04T19:42:37Z
dc.journal.pagination
411-431
dc.journal.pais
Croacia
dc.journal.ciudad
Rijeka
dc.description.fil
Fil: Kornblihtt, Laura Inés. No especifíca;
dc.description.fil
Fil: Carreras, Maria Cecilia. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina. Universidad de Buenos Aires. Facultad de Medicina. Hospital de Clínicas General San Martín. Laboratorio de Metabolismo del Oxígeno; Argentina
dc.description.fil
Fil: Blanco, Guillermo Armando C.. Consejo Nacional de Investigaciones Científicas y Técnicas. Oficina de Coordinación Administrativa Houssay. Instituto de Estudios de la Inmunidad Humoral Prof. Ricardo A. Margni. Universidad de Buenos Aires. Facultad de Farmacia y Bioquímica. Instituto de Estudios de la Inmunidad Humoral Prof. Ricardo A. Margni; Argentina
dc.relation.alternativeid
info:eu-repo/semantics/altIdentifier/url/https://www.intechopen.com/chapters/50722
dc.conicet.paginas
514
dc.source.titulo
Autophagy in Current Trends in Cellular Physiology and Pathology
Archivos asociados